DEVELOPICK™: High-Throughput Developability Assessment To Enable Efficient Formulation Development

By Heonchang Lim and Derrick Katayama, Samsung Biologics

While speed to market remains critical for nearly all activities, the industry is increasingly focused on maximizing the effectiveness of early-stage candidate assessments to predict a given molecule’s chances of success prior to investing heavily in that molecule. To this end, Samsung Biologics created DEVELOPICK™, a rapid developability assessment platform that systematically screens molecules to identify candidates with the best potential for advancement to Investigational New Drug (IND) and Biological License Application (BLA).

An early-stage assessment tool can mitigate development risk and help minimize scale-up risk by facilitating the identification of potential issues — as well as informing the development of strategies to address them — before those issues become major problems. This process also is conducive to developing a more effective drug product.

The DEVELOPICK™ platform only requires 20 mg of material and can perform a risk assessment for new drug candidates within just one month, making it a valuable tool in guiding clients towards success in biotherapeutic development. Combined with the flexibility to accommodate different clients’ varying expectations, periodic meetings, and real-time updates from Samsung Biologics project managers, the DEVELOPICK™ platform reduces risk and cost while engendering greater confidence in a candidate molecule.